

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15665-007US1	Application No. 10/563,389
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Claesson Welsh et al.	
		Filing Date January 5, 2006	Group Art Unit 1614

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	US2001/041670	11/15/2001	Simantov, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL	WO02/076486	10/03/2002	WIPO				
	AM	WO03/077872	09/25/2003	WIPO				
	AN	WO02/064621	08/22/2002	WIPO				
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	J.C. Juarez, et al. "Histidine-proline-rich Glycoprotein has potent antiangiogenic activity mediated through the histidine-proline domain" <u>Cancer Research</u> Vol. 62 (September 15, 2002), pgs. 5344-5350
	AR	R. Simantov, et al. "Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1" <u>The Journal of Clinical Investigation</u> (January 2001) Vol. 107 (1), pgs. 45-52
	AS	A. Olsson, et al. "A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization" <u>Cancer Research</u> Vol. 64 (2004) pgs. 599-605

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 15665-007US1	Application No. 10/563,389
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Claesson Welsh et al.	
		Filing Date January 5, 2006	Group Art Unit 1614

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AT	Hulett M.D., et al. "Murine histidine-rich glycoprotein: Cloning, characterization and cellular origin" <u>Immunology and Cell Biology</u> (2000) 78, pgs. 280-287
	AU	D.J. Borza, et al. "Domain structure and conformation of histidine-roline-rich glycoprotein" <u>Biochemistry</u> (1996) Vol. 35, pgs. 1925-1934
	AV	T. Kolde, et al. "Amino Acid Sequence of Human Histidine-Rich Glycoprotein Derived from the Nucleotide Sequence of its cDNA" <u>Biochemistry</u> Vol. 25 (1986), pgs. 2220-2225
	AW	H.K. Lunen, et al. "Interaction of Heparin with Histidine-rich Glycoprotein" <u>Annals New York Academy of Sciences</u> Vol. 556 (1985), pgs. 181-185

Examiner Signature /Maher Haddad/	Date Considered 02/02/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/